Overview

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, study evaluating IOV-2001 (Adoptive Cell Therapy) composed of autologous PBL (Peripheral Blood Lymphocytes) in patients with CLL/SLL, which has relapsed or is relapsing during treatment with ibrutinib or acalabrutinib.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Iovance Biotherapeutics, Inc.
Treatments:
Interleukin-2